埃拉图姆:Edaravone封装的激动性菌丝通过调整血脑屏障的透性来拯救缺血性脑组织:埃拉图姆
1Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, P. R. China.
Theranostics
|February 3, 2025
概括
这项研究纠正了先前发表的一篇文章DOI. 请参阅最新信息,以获得准确的引用和访问.
科学领域:
- 这个部分不适用,因为摘要只包含了纠正通知.
背景情况:
- 这个部分不适用,因为摘要只包含了纠正通知.
研究的目的:
- 这个部分不适用,因为摘要只包含了纠正通知.
主要方法:
- 这个部分不适用,因为摘要只包含了纠正通知.
主要成果:
- 这个部分不适用,因为摘要只包含了纠正通知.
结论:
- 这个部分不适用,因为摘要只包含了纠正通知.
更多相关视频
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.8K
16:26Setting-up an In Vitro Model of Rat Blood-brain Barrier BBB: A Focus on BBB Impermeability and Receptor-mediated Transport
Published on: June 28, 2014
42.4K
相关概念视频
00:49The Blood-brain Barrier
46.6K
Overview
46.6K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
219
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
219